Our colleagues at Recipharm recently completed an important study in COVID-19 patients in Milan, Italy. This study was the first to look at Health-Related Quality of Life (HRQoL) in COVID-19 patients discharged from the hospital setting.
Read More
Dear Shareholders and Stakeholders:
I hope you are faring well as we all continue to navigate life amidst the coronavirus pandemic. The Alitair team is doing fine and we hope you are too. From a business standpoint, we continue to work hard at driving the business forward although the current and recent past business environments have made capital-raising activities even more challenging than normal. Notwithstanding these setbacks, and the unprecedented impacts of the SARS-CoV-2 pandemic, we believe our product portfolio remains attractive, our target markets remain large, and the unmet medical needs remain unfulfilled. We also believe that Alitair still holds fundamental attractiveness from a therapeutic area standpoint and from a valuation standpoint.
Read More
Alitair Pharmaceuticals would like to alert our shareholders and stakeholders that Recipharm, our in-licensing partner for ALT-09 (ERDOSTEINE), announced the initiation of an ERDOSTEINE clinical trial in COVID-19 patients in Italy as part of a post-discharge treatment protocol.
Read MoreThe Alitair Pharmaceuticals Executive Team would like to wish our shareholders and stakeholders a Happy New Year!
To kick off the year, Alitair will be participating in the J.P. Morgan Healthcare Conference in San Francisco, CA from January 11th - 15th. This is one of the preeminent meetings in 2020 for biopharma and it is a great way to start the year. Alitair will be meeting with both potential funders (as we seek capital to drive the product development program forward) and potential partners (as we seek to identify value-creating transactions for our pipeline assets). Specifically, we seek biopharma companies who wish to license, co-develop or co-commercialize our valuable assets. Current efforts are focused on our lead assets benzonatate polacrilex tablets and the Overdose Reduction (ODR) formulation technology. To schedule a meeting at JPM, contact Frank Koos, SVP, Corporate and Business Development at fkoos@alitair.com.
Read MoreDear Shareholders and Stakeholders,
As we approach the end of the 2nd Quarter, I wanted to provide an update on our business and our planned endeavors for 3Q19. Overall, our executive team is working diligently to make sure the promise of Alitair remains alive and that our firm remains very investable. Our target markets, our pipeline, our intellectual property, our clinical development and our regulatory strategy all remains very viable. And, the long-term opportunity to capture increasing value for shareholders and stakeholders is exciting.
Read MoreALITAIR will attend the 37th annual J.P. Morgan Healthcare Conference from January 7-10, 2019 in San Francisco, California. The J.P. Morgan Healthcare Conference is one of largest conferences in the life sciences industry.
Read MoreNow that 2018 has ended, I would like to provide an update to our external shareholders and stakeholders. First, I would like to reaffirm that the potential of the Alitair pipeline remains strong and relevant in terms of meeting unmet medical needs. Our valuation has held firm. And, helping treat respiratory disease and providing solutions for the Opioid Crisis are central to our mission.
Read MoreDear Valued Alitair Shareholder,
I want to provide you with a brief update on Alitair Pharmaceuticals.
Critical Need for More Capital
Alitair requires additional capital to fund its 24-month Clinical Development Plan and for General Corporate Purposes. I am limited to what I can say as Alitair is working through the final steps of a closing process to raise capital with two funding sources -- one a new investment fund that targets Alternate Investment from endowment funds from major non-profit health systems and the other a Healthcare Investment Bank. Together, these two entities will provide new capital to help grow our company.
Read MoreAlitair launches a Facebook page — focused on biopharma news and information relevant to the therapeutics areas of our medicines. This includes bronchiectasis, cough, and providing solutions for the abuse and misuse of prescription drugs. You can find the Alitair Facebook page at www.facebook.com/alitairpharma. Please “Like” and “Follow” our Alitair Facebook page.
Read MoreAlitair Pharmaceuticals CEO, James Hoyes, presents the corporate overview and strategic direction during the National Investment Banking Association (NIBA) Meeting in NYC. The meeting ran February 27-28, 2017.
Mr. Hoyes focused on the proprietary ion-exchange resin formulation technology that supports the highly innovative Overdose Reduction technology and forms the basis of its non-narcotic and narcotic prescription cough medicines portfolio. The Overdose Reduction technology, called ODR, may serve as a significant product in the fight against the Opioid Crisis. ODR serves to minimize the risk of overdose due to the abuse and/or misuse of prescription medicines especially opioids and benzodiazepines. Mr. Hoyes also reviewed the portfolio of Orphan Drugs focused on the rare pulmonary disease called bronchiectasis.
Read MoreAlitair Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on respiratory health, today announced the issuance of U.S. Patent No. 9,211,292, covering its prescription drug overdose reduction technology, ODR™ .
Read MoreAlitair Pharmaceuticals, Inc., a clinical stage pharmaceutical company with multiple respiratory product candidates in development, announced today that it has been selected to present at the Cavendish Global Health Impact Forum co-hosted by the Cleveland Clinic in Cleveland, Ohio, October 25 - 28, 2015.
Read More